Join Growin Stock Community!

瑞基4171.TW Overview

TW StockAgr. Science & Tech.
(No presentation for 4171)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

瑞基（4171）Overall Performance

瑞基（4171）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

瑞基（4171） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

瑞基（4171）Key Information

瑞基（4171）Profile

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. It also provides polymerase chain reaction training programs (PCR), molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services. It serves aquaculture, agriculture, food, and human health industries, as well as companion animals and livestock. The company was founded in 2004 and is headquartered in Taichung, Taiwan.

瑞基（4171）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
3.17
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.25%
Net Margin
-68.95%
Revenue Growth (YoY)
1.87%
Profit Growth (YoY)
141.21%
3-Year Revenue Growth
-45.13%
3-Year Profit Growth
-46.98%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
3.17
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
67.25%
Net Margin
-68.95%
Revenue Growth (YoY)
1.87%
Profit Growth (YoY)
141.21%
3-Year Revenue Growth
-45.13%
3-Year Profit Growth
-46.98%
default symbol

4171

瑞基

19.75D

-1.01%

(-0.01)

  • When is 4171's latest earnings report released?

    The most recent financial report for 瑞基 (4171) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4171's short-term business performance and financial health. For the latest updates on 4171's earnings releases, visit this page regularly.

  • What is the operating profit of 4171?

    According to the latest financial report, 瑞基 (4171) reported an Operating Profit of -24.16M with an Operating Margin of -45.24% this period, representing a growth of 9.41% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4171's revenue growth?

    In the latest financial report, 瑞基 (4171) announced revenue of 53.39M, with a Year-Over-Year growth rate of -14.52%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4171 have?

    At the end of the period, 瑞基 (4171) held Total Cash and Cash Equivalents of 104.88M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4171 go with three margins increasing?

    In the latest report, 瑞基 (4171) did not achieve the “three margins increasing” benchmark, with a gross margin of 64.07%%, operating margin of -45.24%%, and net margin of -69.81%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4171's profit trajectory and future growth potential.

  • Is 4171's EPS continuing to grow?

    According to the past four quarterly reports, 瑞基 (4171)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4171?

    瑞基 (4171)'s Free Cash Flow (FCF) for the period is -13.41M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 150.68% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.